Do analysts recommend SKYE or GNPX?

Skye Bioscience presently has a consensus price target of $8.50, indicating a potential upside of 1,264.37%. Given Skye Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Skye Bioscience is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, SKYE or GNPX?

Genprex is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.44 N/A Genprex N/A N/A -$16.23M -$14.14 N/A

Is SKYE or GNPX more profitable?

Skye Bioscience's return on equity of -217.27% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% Genprex N/A -247.32% -176.73%

Does the media refer more to SKYE or GNPX?

In the previous week, Genprex had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 4 mentions for Genprex and 3 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 0.47 beat Genprex's score of -0.03 indicating that Skye Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genprex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MRKR or GNPX?

Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 657.00%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MRKR or GNPX more profitable?

Genprex has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Marker Therapeutics -343.03% -73.29% -59.70% Genprex N/A -247.32% -176.73%

Do analysts rate TXMD or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TXMD or GNPX more profitable?

TherapeuticsMD has a net margin of 5.34% compared to Genprex's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets TherapeuticsMD 5.34% 0.32% 0.23% Genprex N/A -247.32% -176.73%

Do analysts rate TVGN or GNPX?

Tevogen Bio currently has a consensus price target of $100.00, indicating a potential upside of 2,150.73%. Given Tevogen Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Tevogen Bio is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, TVGN or GNPX?

Tevogen Bio is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.61 N/A Genprex N/A N/A -$16.23M -$14.14 N/A

Is TVGN or GNPX more profitable?

Tevogen Bio's return on equity of 0.00% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% Genprex N/A -247.32% -176.73%

Does the media refer more to TVGN or GNPX?

In the previous week, Genprex had 2 more articles in the media than Tevogen Bio. MarketBeat recorded 4 mentions for Genprex and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.93 beat Genprex's score of -0.03 indicating that Tevogen Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genprex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GNPX or MDCX?

Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 2,178.48%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher earnings and valuation, GNPX or MDCX?

Genprex is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$14.14 N/A Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is GNPX or MDCX more profitable?

Genprex's return on equity of -247.32% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -247.32% -176.73% Medicus Pharma N/A -3,137.84% -311.33%

Does the media favor GNPX or MDCX?

In the previous week, Medicus Pharma had 1 more articles in the media than Genprex. MarketBeat recorded 5 mentions for Medicus Pharma and 4 mentions for Genprex. Medicus Pharma's average media sentiment score of 1.17 beat Genprex's score of -0.03 indicating that Medicus Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genprex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medicus Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Genprex (GNPX) Competitors

$8.06 -2.74 (-25.37%)

As of 03:50 PM Eastern

Compare

GNPX vs. SKYE, MRKR, TXMD, TVGN, and MDCX

Should you buy Genprex stock or one of its competitors? MarketBeat compares Genprex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genprex include Skye Bioscience (SKYE), Marker Therapeutics (MRKR), TherapeuticsMD (TXMD), Tevogen Bio (TVGN), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry.

How does Genprex compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Genprex is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

Skye Bioscience has a beta of 2.94, indicating that its stock price is 194% more volatile than the broader market. Comparatively, Genprex has a beta of -0.92, indicating that its stock price is 192% less volatile than the broader market.

Skye Bioscience presently has a consensus price target of $8.50, indicating a potential upside of 1,264.37%. Given Skye Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Skye Bioscience is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Genprex had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 4 mentions for Genprex and 3 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 0.47 beat Genprex's score of -0.03 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genprex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by insiders. Comparatively, 0.3% of Genprex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Skye Bioscience's return on equity of -217.27% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Genprex	N/A	-247.32%	-176.73%

Summary

Skye Bioscience beats Genprex on 12 of the 14 factors compared between the two stocks.

How does Genprex compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 657.00%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 0.3% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Genprex had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 4 mentions for Genprex and 2 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.44 beat Genprex's score of -0.03 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Marker Therapeutics	Positive
Genprex	Neutral

Genprex has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Genprex	N/A	-247.32%	-176.73%

Marker Therapeutics has higher revenue and earnings than Genprex. Marker Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.20	-$12.16M	-$0.61	N/A
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

Marker Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Genprex has a beta of -0.92, suggesting that its stock price is 192% less volatile than the broader market.

Summary

Marker Therapeutics beats Genprex on 12 of the 15 factors compared between the two stocks.

How does Genprex compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, Genprex had 3 more articles in the media than TherapeuticsMD. MarketBeat recorded 4 mentions for Genprex and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.89 beat Genprex's score of -0.03 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
Genprex	Neutral

TherapeuticsMD has higher revenue and earnings than Genprex. Genprex is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.82	-$570K	$0.06	34.00
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has a net margin of 5.34% compared to Genprex's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Genprex	N/A	-247.32%	-176.73%

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by company insiders. Comparatively, 0.3% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

TherapeuticsMD has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Genprex has a beta of -0.92, suggesting that its share price is 192% less volatile than the broader market.

Summary

TherapeuticsMD beats Genprex on 11 of the 12 factors compared between the two stocks.

How does Genprex compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Tevogen Bio is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

Tevogen Bio currently has a consensus price target of $100.00, indicating a potential upside of 2,150.73%. Given Tevogen Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Tevogen Bio is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Genprex had 2 more articles in the media than Tevogen Bio. MarketBeat recorded 4 mentions for Genprex and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.93 beat Genprex's score of -0.03 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genprex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tevogen Bio has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Genprex has a beta of -0.92, suggesting that its stock price is 192% less volatile than the broader market.

14.1% of Genprex shares are owned by institutional investors. 70.5% of Tevogen Bio shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tevogen Bio's return on equity of 0.00% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Genprex	N/A	-247.32%	-176.73%

Summary

Tevogen Bio beats Genprex on 7 of the 12 factors compared between the two stocks.

How does Genprex compare to Medicus Pharma?

Genprex (NASDAQ:GNPX) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

14.1% of Genprex shares are held by institutional investors. 0.3% of Genprex shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Genprex has a beta of -0.92, suggesting that its share price is 192% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 2,178.48%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Medicus Pharma had 1 more articles in the media than Genprex. MarketBeat recorded 5 mentions for Medicus Pharma and 4 mentions for Genprex. Medicus Pharma's average media sentiment score of 1.17 beat Genprex's score of -0.03 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genprex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genprex is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Genprex's return on equity of -247.32% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-247.32%	-176.73%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Summary

Medicus Pharma beats Genprex on 9 of the 13 factors compared between the two stocks.

Get Genprex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNPX vs. The Competition

Export

Metric	Genprex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$87.93M	$3.67B	$6.85B	$12.46B
Dividend Yield	N/A	2.22%	2.68%	9.44%
P/E Ratio	-0.57	21.00	27.16	24.23
Price / Sales	N/A	175.83	510.03	87.66
Price / Cash	N/A	143.89	48.63	60.03
Price / Book	3.33	8.35	10.78	6.22
Net Income	-$16.23M	$23.83M	$3.59B	$331.94M
7 Day Performance	-34.05%	-5.42%	-2.63%	-1.94%
1 Month Performance	-15.91%	5.02%	2.68%	-0.99%
1 Year Performance	-97.50%	45.06%	25.02%	18.02%

Genprex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNPX Genprex	0.6536 of 5 stars	$8.06 -25.4%	N/A	-96.7%	$87.93M	N/A	N/A	20	News Coverage Gap Down
SKYE Skye Bioscience	2.1726 of 5 stars	$0.70 flat	$8.50 +1,113.4%	-83.8%	$24.62M	N/A	N/A	11	Gap Up
MRKR Marker Therapeutics	3.2169 of 5 stars	$1.47 flat	$10.00 +580.3%	-10.2%	$24.51M	$3.55M	N/A	60	Short Interest Decrease
TXMD TherapeuticsMD	1.3313 of 5 stars	$2.11 flat	N/A	+70.9%	$24.41M	$3.02M	35.17	420	Positive News
TVGN Tevogen Bio	1.8459 of 5 stars	$5.77 flat	$100.00 +1,633.1%	-92.0%	$24.18M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNPX) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genprex (GNPX) Competitors

GNPX vs. SKYE, MRKR, TXMD, TVGN, and MDCX

How does Genprex compare to Skye Bioscience?

Summary

How does Genprex compare to Marker Therapeutics?

Summary

How does Genprex compare to TherapeuticsMD?

Summary

How does Genprex compare to Tevogen Bio?

Summary

How does Genprex compare to Medicus Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genprex (GNPX) Competitors

GNPX vs. SKYE, MRKR, TXMD, TVGN, and MDCX

How does Genprex compare to Skye Bioscience?

Which has preferable earnings & valuation, SKYE or GNPX?

Which has more volatility & risk, SKYE or GNPX?

Do analysts recommend SKYE or GNPX?

Does the media refer more to SKYE or GNPX?

Do institutionals and insiders believe in SKYE or GNPX?

Is SKYE or GNPX more profitable?

Summary

How does Genprex compare to Marker Therapeutics?

Do analysts rate MRKR or GNPX?

Do institutionals and insiders have more ownership in MRKR or GNPX?

Does the media refer more to MRKR or GNPX?

Is MRKR or GNPX more profitable?

Which has better valuation and earnings, MRKR or GNPX?

Which has more risk and volatility, MRKR or GNPX?

Summary

How does Genprex compare to TherapeuticsMD?

Does the media refer more to TXMD or GNPX?

Which has higher earnings & valuation, TXMD or GNPX?

Do analysts rate TXMD or GNPX?

Is TXMD or GNPX more profitable?

Do institutionals & insiders believe in TXMD or GNPX?

Which has more risk and volatility, TXMD or GNPX?

Summary

How does Genprex compare to Tevogen Bio?

Which has preferable valuation & earnings, TVGN or GNPX?

Do analysts rate TVGN or GNPX?

Does the media refer more to TVGN or GNPX?

Which has more volatility and risk, TVGN or GNPX?

Do institutionals and insiders believe in TVGN or GNPX?

Is TVGN or GNPX more profitable?

Summary

How does Genprex compare to Medicus Pharma?

Do insiders & institutionals have more ownership in GNPX or MDCX?

Which has more risk & volatility, GNPX or MDCX?

Do analysts prefer GNPX or MDCX?

Does the media favor GNPX or MDCX?

Which has higher earnings and valuation, GNPX or MDCX?

Is GNPX or MDCX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools